Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14904384 | 0.81 | — | — | |
| SCHEMBL15130876 | 0.77 | HMGCR (0.42) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL17300290 | 0.77 | HMGCR (0.42) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL16787497 | 0.77 | — | — | |
| SCHEMBL12931502 | 0.77 | — | — | |
| SCHEMBL12135731 | 0.75 | TSHR (0.38) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL14904382 | 0.75 | — | — | |
| SCHEMBL14135896 | 0.74 | ALDH1A1 (0.36) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL87457 | 0.74 | NAALAD2 (0.38) | TSHRALDH1A1HIF1A | |
| SCHEMBL10301462 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355734-A1 | Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor | UNIVERSITE DE STRASBOURG (FR) | 2017-12-14 | — | — | US | disclosed |
| US-20150112042-A1 | Antigen Delivery Vectors and Constructs | ALTIMMUNE UK LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| US-8759281-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2014-06-24 | — | — | US | disclosed |
| US-20120315293-A1 | Antigen Delivery Vectors and Constructs | IMMUNE TARGETING SYSTEMS LTD. | 2012-12-13 | — | — | US | disclosed |
| US-8129333-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20120034259-A1 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | ALTIMMUNE UK LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112042-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | TSHR 3438/4885ALDH1A1 3392/4885CYP2D6 4674/4885 |
| US-20120315293-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | TSHR 3438/4885ALDH1A1 3392/4885CYP2D6 4674/4885 |
| US-20170355734-A1 | Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor | APLNR, AVPR2, AVPR1A | TSHR 297/4885ALDH1A1 1151/4885CYP2D6 3020/4885 |
| US-20120034259-A1 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | LY96, CD74, CD69 | TSHR 3438/4885ALDH1A1 3392/4885CYP2D6 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.